Mammalian cell-derived somatropin : a review of its use in the management of HIV-associated wasting

Drugs
David R Goldsmith, Antona J Wagstaff

Abstract

HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormone) derived from mammalian cells (Serostim) is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting. Somatropin 0.1 mg/kg/day administered subcutaneously for 12 weeks effectively increased work output, bodyweight and lean body mass and improved health-related quality of life (HR-QOL), compared with placebo, and had a generally manageable tolerability profile in a large randomised study in patients with HIV-associated wasting. Potential areas for further research include determination of longer-term efficacy and tolerability, the cost effectiveness of treatment, the optimal somatropin dosage, management of patients after 12 weeks' therapy and whether maintenance strategies might exist to maintain accrued lean body mass with lower doses of somatropin. Nevertheless, indications to date are that somatropin is likely to have an important role...Continue Reading

References

Sep 15, 1994·Annals of Internal Medicine·J H Von RoennS A Weitzman
Sep 15, 1994·Annals of Internal Medicine·M H OsterN M Flynn
Dec 16, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·T N Kakuda
Apr 20, 1999·JAMA : the Journal of the American Medical Association·A StrawfordM K Hellerstein
Feb 22, 2000·JAMA : the Journal of the American Medical Association·S BhasinG Beall
Apr 13, 2000·Mayo Clinic Proceedings·P M NemechekM S Gottlieb
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A WankeS L Gorbach
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P RietschelS Grinspoon
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·S Grinspoon, M Gelato
Oct 24, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alice M TangSherwood L Gorbach
Apr 13, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Donald P KotlerUNKNOWN Serostim in Adipose Redistribution Syndrome Study Group
Mar 16, 2005·Archives of Internal Medicine·Kathleen MulliganUNKNOWN National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group
Aug 27, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alice M TangChristine Wanke

❮ Previous
Next ❯

Citations

Jun 15, 2010·Journal of Biomaterials Science. Polymer Edition·Pawel W DrapalaVictor H Pérez-Luna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.